Bell HN, Stockwell BR, Zou W
Mechanism Avg % weight loss (placebo subtracted) Dosing Side effects Cost Semaglutide GLP-1 receptor agonist : (increases insulin secretion, suppresses appetite, enhances satiety, slows gastric emptying) STEP 1 14.9% (68 weeks) STEP 5 (120 weeks): -16.5% ~1517% average sustained loss 20% loss in ~17% of users 2.4mg weekly Nausea (44%) Diarrhea (30%) Vomiting (24%) Constipation (23%) Headache, fatigue Varies widely but generally the cheaper of the two
In 2015, Glenmark was the first to launch the DPP4 inhibitor, Teneligliptin (Zita Plus and Ziten), followed by a FDC of Teneligliptin + Metformin (Zita-Met Plus and Ziten-M)
But if you want to ensure thats true for you, youll want to manage the side effects as best as you can
Dariush Mozaffarian, cardiologist and director of the Food is Medicine Institute at the Gerald J